Efficacy and Safety of Omibtasvir, Paritaprevir and Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Patients | ||||
The Medical Journal of Cairo University | ||||
Article 71, Volume 88, March, March 2020, Page 573-575 PDF (226.38 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mjcu.2020.104608 | ||||
View on SCiNiTO | ||||
Authors | ||||
HASAN S. MAHMOUD, M.D.; SHAMARDAN E.S. BAZEED, M.D.; MOHAMED S. MOHAMED, M.Sc. | ||||
The Department of Hepatology, Gastroenterology and Infectious Diseases, Qina Faculty of Medicine, South Valley University* and Qina Fever Hospital, Ministry of Health**, Qina City, Egypt | ||||
Abstract | ||||
Abstract Background: The highest prevalence of chronic Hepatitis C Virus (HCV) was reported in Egypt. DAAs has been avail-able, with a reported 12 weeks sustained virologic response (12w-SVR) above 95% after treatment for 12 weaks. Aim of Study: Aim of the current study was to evaluate evaluate efficacy of the 2-DAAs combination of ombitasvir, paritaprevir (co-dosed with ritonavir) with ribavirin in treatment of chronic HCV patients and evaluate correlation between virologic failure and risk factors. Patients and Methods: Chronic HCV patients (n=100) were enrolled in the current study. All patients received 25mg ombitasvir, 150mg paritaprevir, and 100mg ritonavir orally once daily plus Ribavirin 600-1000mg) for 12 weaks. Response was assessed 12 weeks after end of treatment by SRT-PCR. Results: The interferon-free regimen of ombitasvir/ pari-taprevir/ritonavir + ribavirin for 12 weeks achieved sustained virologic response in 91% of patients. Conclusion: In conclusion, the 12-week 2-DAA regimen of OBV/PTV/r and DSV achieved an SVR12 rate of 91% in previously untreated patients with HCV infection. Liver Cirrhosis has negative impact on 12 weeks-SVR. Conflict of Interest: The authors have no conflict of interest related to this publication. | ||||
Keywords | ||||
Ombitasvir; Paritaprevir; HCV | ||||
Statistics Article View: 144 PDF Download: 92 |
||||